US court dismisses COVID-19 vaccine suit against Genevant, Arbutus

New Jersey federal judge said Acuitas had failed to show case or controversy | Acuitas had sought declaratory judgment that Pfizer’s Comirnaty vaccine did not infringe patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

CureVac and Acuitas wind up COVID-19 vaccine dispute

30 April 2024 Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech.

Big Pharma

Pfizer must hand over COVID-19 vaccine knowledge

19 September 2023 Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

US court dismisses COVID-19 vaccine suit against Genevant, Arbutus

More on this story

Editor's picks

Editor's picks

More features